Cell Signaling Technology, Inc. (CST) has announced an agreement with Novartis under which a pilot study was performed using CST's PhosphoScan™ technology to identify phosphorylation sites and ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing ...
The study took place at sites in the UK, Australia, New Zealand and the European Union. Results showed that the combination of CST-103/CST-107 was both safe and well-tolerated, and importantly, that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback